/NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES OR DISSEMINATION IN
THE UNITED STATES/
CALGARY, July 16, 2013 /CNW/ - PACEpartners Inc. (TSXV:PIA)
(PACEpartners) is pleased to announce that its operating subsidiary
Vivione Biosciences, LLC (Vivione) has appointed Quip Laboratories
(Quip) as a distribution partner in the US and Canada for the seafood
and fresh produce food safety markets.
Vivione's RAPID-B system is able to provide pathogen detection down to a
single cell in seven hours or less (including sample preparation)
versus the 24 hours up to several days that it takes with competitive
systems. The rapid time-to-results capability allows food processors to
more closely monitor their manufacturing plants, incoming raw
materials, as well as mitigate the risk of a food safety recall.
According to Kevin Kuykendall, PACEpartners' CEO: "Quip's excellent
customer relationships and their tradition of product innovation over
the past 30 years make them a natural distribution partner for the
introduction of the RAPID-B system into the seafood and fresh produce
markets. Quip has already purchased a RAPID-B system for demonstrations
and we look forward to working closely with them over the coming years
to introduce this new technology to the market."
According to Tim Hidell, Quip's CEO: "Vivione's RA PID-B platform could
revolutionize the produce and seafood diagnostic markets. RAPID-B's
ability to detect a single cell of bacteria in seven hours or less will
provide food producers with the ability to reduce chemical costs,
reduce inventory hold times, optimize manufacturing efficiencies, and
ultimately reduce their product recall risk. We're excited to work with
Vivione to introduce this new technology."
Vivione Biosciences, LLC, the operating subsidiary of PACEpartners
Inc.(TSXV:PIA), is a life sciences diagnostic company who collaborated
with the Food and Drug Administration's National Center for
Toxicological Research (NCTR) over six years to develop RAPID-B.
Vivione's RAPID-B system provides for the rapid detection of bacterial
pathogens applicable to the food safety, clinical diagnostics and other
markets including agricultural, water testing, pharmaceutical, and
medical device applications. Vivione's business is centered on the
commercialization of the new ultra high performance RAPID-B, an
integrated diagnostic system consisting of hardware, software and
wetware that tests bacteria in key environments and provides test
results in seven hours or less, including sample preparation. This
technology has diverse applicability from food safety to clinical
diagnostics by rapidly identifying and quantifying microorganism levels
down to a single cell.
Since its founding in 1985, Quip Laboratories, Inc. has been devoted to
its mission of identifying, creating and delivering innovative
technologies that enable the safest and most eco-gentle outcomes for
clients across several industry sectors. Through this singular
strategic commitment, Quip Laboratories has set the standards for
biosafety and quality. The company's critical process monitoring
programs feature in-line validation, to verify effective cleaning and
sanitation. The company compliments its novel technologies with an
array of professional services that clients have come to consider
essential adjuncts to their own capabilities. The company is
headquartered in Wilmington, Delaware, and can be found on the web at www.quiplabs.com. For more information, contact Quip Laboratories at 1-800-424-2436
This news release contains "forward-looking statements" within the
meaning of applicable securities laws. Although PACEpartners believes
that the expectations reflected in its forward-looking statements are
reasonable, such statements have been based on factors and assumptions
concerning future events that may prove to be inaccurate. These factors
and assumptions are based upon currently available information to
PACEpartners. Such statements are subject to known and unknown risks,
uncertainties and other factors that could influence actual results or
events and cause actual results or events to differ materially from
those stated, anticipated or implied in the forward-looking statements.
Readers are cautioned to not place undue reliance on forward-looking
statements. The statements in this press release are made as of the
date of this release and, except as required by applicable law,
PACEpartners does not undertake any obligation to publicly update or to
revise any of the included forward-looking statements, whether as a
result of new information, future events or otherwise. PACEpartners
undertakes no obligation to comment on analyses, expectations or
statements made by third-parties in respect of PACEpartners, Vivione or
its financial or operating results or (as applicable), their
The securities mentioned herein have not been and will not be registered
under the United States Securities Act of 1933, as amended, or the
securities laws of any state, and may not be offered or sold in the
United States absent registration or an applicable exemption from
registration requirements. This press release does not constitute an
offer to sell or the solicitation of any offer to buy these securities
in any jurisdiction.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICE PROVIDER (AS
THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE)
ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE: PACEpartners Inc.
For further information:
Chief Executive Officer
Tel: (214) 886-5733
Quip Laboratories, Inc.
Chief Executive Officer